Tuesday, November 5, 2024

LANGaware Partners with Bioiatriki for Alzheimer’s Detection

Related stories

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Absci Corporation a data-first generative AI drug creation company, and...

GreyNoise Intelligence Discovers Zero-Day Vulnerabilities in Live Streaming Cameras with the Help of AI

GreyNoise Intelligence, the cybersecurity company providing real-time, verifiable threat...

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials

Medidata, a Dassault Systèmes brand and leading provider of...

Blend Appoints Mike Mischel as SVP of AI Consulting

Blend, a leader in data science and AI-powered solutions,...

Patronus AI Launches Industry-First Self-Serve API for AI Evaluation and Guardrails

Patronus AI announced the launch of the Patronus API, the first...
spot_imgspot_img

LANGaware, a pioneering AI-driven healthcare technology company, has entered into a strategic partnership with the Bioiatriki Healthcare Group, one of Southeast Europe’s largest private healthcare providers. This collaboration aims to advance the early detection and management of neurodegenerative conditions, such as Alzheimer’s Disease and Mild Cognitive Impairment (MCI), in Greece and Cyprus.

Under this partnership, Bioiatriki integrates with LANGaware’s advanced AI-driven platform into its extensive network of over 75 diagnostic centers. This platform leverages AI to analyze digital biomarkers from voice and speech, enabling early detection of cognitive and behavioral health conditions with unmatched accuracy. By offering this cutting-edge technology, Bioiatriki empowers patients to detect dementia symptoms at their earliest stages, significantly enhancing patient outcomes and quality of life.

“We are excited to collaborate with Bioiatriki Healthcare Group to bring our innovative technology to more patients,” said Dr. Vassiliki Rentoumi, Founder and CEO of LANGaware. “This partnership aligns with our mission to revolutionize early diagnosis and provide effective, accessible solutions for cognitive health management globally.”

Also Read: Exo Launches SweepAI™: Smart Ultrasound Revolution

LANGaware’s platform provides rapid and accurate results within minutes, requiring only a brief voice recording of the participant describing an image or a daily activity. The system boasts a sensitivity of 90% and a specificity of 85% in detecting Alzheimer’s Disease and MCI, significantly reducing the risk of misdiagnosis and unnecessary treatments.

The integration of LANGaware’s technology within Bioiatriki‘s healthcare services is expected to not only improve patient outcomes but also enhance healthcare efficiency by enabling timely interventions and personalized support. This partnership marks a significant step forward in expanding access to advanced diagnostic services and represents a shared commitment to improving cognitive health management.

LANGaware leverages AI technology to revolutionize cognitive and behavioral health screening. By utilizing speech analysis and proprietary voice and speech biomarkers, LANGaware provides early, accurate and objective detection of conditions, enabling more effective treatments, reducing healthcare burdens, and improving overall well-being.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img